-
This publication is an update on osteoporosis screening from the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation.
-
Over the years, different tocolytics have been in vogue, only to be discarded later because meta-analyses showed that the agent simply did not work. This month's review will focus on nifedipine, a medication that has been in and out of favor for more than 20 years.
-
-
In the vulvar vestibulitis clinical trial conducted at the University of Rochester between 2002 and 2007, patients with vulvar vestibulitis syndrome (localized provoked vulvodynia) were enrolled in a 12-week randomized, placebo-controlled treatment trial.
-
The investigators prospectively enrolled and followed a cohort of 97 teens before and six, 12, and 18 months after starting DMPA.
-
Is your facility participating in National HIV Testing Day on June 27? If not, you may be missing an important community outreach opportunity to help people learn their HIV status.
-
Since results of the 2002 Women's Health Initiative (WHI) report suggested that use of menopausal hormone therapy increases risk of coronary heart disease, science has examined the timing of therapy initiation on safe use of such treatment.
-
Four hundred thousand (1.6% of U.S. adolescents) experience serious physical and/or sexual dating violence each year.
-
Trichomoniasis is the most common curable sexually transmitted infection (STI) in young, sexually active women, according to the Centers for Disease Control and Prevention. An estimated 7.4 million new cases occur each year in U.S. women and men.
-
Amphora, under development by Evofem of San Diego, is a bioadhesive acid-buffering gel that coats the vaginal wall and cervix. Amphora helps maintain a woman's natural pH level between 3.8 and 4.2.